Drug intelligence / Profile preview

NRNT-072601

Development stage: Preclinical
Lead developer: Neurentis
Modality: Small Molecules
Administration: Sublingual

Overview

NRNT-072601 is a preclinical-stage therapeutic candidate developed by Neurentis for the treatment of Multiple System Atrophy (MSA) and Perry Syndrome. The drug is formulated as a sublingual film, a delivery method designed to improve bioavailability and patient compliance in neurodegenerative conditions. Neurentis is actively pursuing orphan drug designation for this asset to support its development for these rare and debilitating disorders.

Beyond the preview

Go deeper on NRNT-072601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRNT-072601.

Explore the full profile